BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 27455819)

  • 21. [Comparative clinical and epidemiological evaluation of beta-lactam antibiotics in the treatment of intraabdominal infections].
    Beketov AS; Sidorenko SV; Pisarev VV; Komarov RM
    Antibiot Khimioter; 2003; 48(3):34-41. PubMed ID: 12914120
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Laboratory and clinical study of sulbactam/cefoperazone (SBT/CPZ) on bacterial prostatitis].
    Suzuki K; Horiba M
    Hinyokika Kiyo; 1991 Oct; 37(10):1333-43. PubMed ID: 1755429
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinical effectiveness of cefoperazone-sulbactam vs. piperacillin-tazobactam for the treatment of pneumonia in elderly patients.
    Huang CT; Chen CH; Chen WC; Wang YT; Lai CC; Fu PK; Kuo LK; Chen CM; Fang WF; Tu CY; Ku SC
    Int J Antimicrob Agents; 2022 Jan; 59(1):106491. PubMed ID: 34871744
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Efficacy and safety of generic cefoperazone/sulbactam versus branded cefoperazone/sulbactam in the treatment of bacterial infections: a systematic review and meta-analysis.
    Wu R; Wang X; Cui P; Chen W; Yang W; Lai Y
    J Chemother; 2024 Apr; ():1-11. PubMed ID: 38644652
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The effect of cefoperazone sulbactam and piperacillin tazobactam on mortality in Gram-negative nosocomial infections.
    Guclu E; Kaya G; Ogutlu A; Karabay O
    J Chemother; 2020 May; 32(3):118-123. PubMed ID: 32096456
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cefoperazone-sulbactam combination in the treatment of urinary tract infections: efficacy, safety, and effects on coagulation.
    Greenberg RN; Reilly PM; Weinandt WJ; Bollinger M; Kennedy DJ
    Clin Ther; 1987; 10(1):52-6. PubMed ID: 3329965
    [TBL] [Abstract][Full Text] [Related]  

  • 27. An open trial of cefoperazone plus sulbactam for the treatment of fever in cancer patients.
    Bodey GP; Elting LS; Narro J; Koller C; O'Brien S; Estey E; Benjamin R
    J Antimicrob Chemother; 1993 Jul; 32(1):141-52. PubMed ID: 8226405
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Clinical experience with chemotherapy using sulbactam/cefoperazone for severe infections accompanying malignant hematological disorders].
    Fujii Y; Ayame H; Inoue H; Fujita N; Miyoshi K; Murano K; Hatao K; Yaga K; Kaku K; Kaneko T
    Jpn J Antibiot; 1990 Jun; 43(6):1143-51. PubMed ID: 2232145
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [A randomized controlled clinical trial of sulperazone as compared with cefotaxime in the treatment of bacterial infections].
    Li J; Miao J; Hu W
    Zhonghua Nei Ke Za Zhi; 1995 Oct; 34(10):680-2. PubMed ID: 8731830
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The clinical efficacy of cefoperazone-sulbactam versus piperacillin-tazobactam in the treatment of severe community-acquired pneumonia.
    Lai CC; Chen WC; Kuo LK; Wang YT; Fu PK; Ku SC; Fang WF; Chen CM; Tu CY; Cheng WC; Chen CH
    Medicine (Baltimore); 2023 Jul; 102(28):e34284. PubMed ID: 37443505
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Randomized comparison of sulbactam/cefoperazone with imipenem as empirical monotherapy for febrile granulocytopenic patients.
    Winston DJ; Bartoni K; Bruckner DA; Schiller GJ; Territo MC
    Clin Infect Dis; 1998 Mar; 26(3):576-83. PubMed ID: 9524826
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [A trial of using sulperazone (cefoperazone/sulbactam) in the combined treatment of patients with a burn infection].
    Iakovlev VP; Krutikov MG; Alekseev AA; Grishina IA; Izotova GN; Kashin IuD
    Antibiot Khimioter; 1995 May; 40(5):38-41. PubMed ID: 8534180
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Clinical evaluation of sulbactam/cefoperazone for infections during the chemotherapy of hematologic malignancy].
    Kawai Y; Ueda T; Iwasaki H; Nakamura T
    Jpn J Antibiot; 1994 Sep; 47(9):1196-201. PubMed ID: 7990260
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Use of a combination of cefoperazone with sulbactam for treatment of patients with wound infections].
    Iakovlev VP; Blatun LA; Puchkova LS; Svetukhin AM
    Antibiot Khimioter; 1994 Dec; 39(12):31-4. PubMed ID: 7733785
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Piperacillin/tazobactam vs. cefoperazone/sulbactam in adult low-risk febrile neutropenia cases.
    Sipahi OR; Arda B; Nazli-Zeka A; Pullukcu H; Tasbakan M; Yamazhan T; Ozkoren-Calik S; Sipahi H; Ulusoy S
    Int J Clin Pract; 2014 Feb; 68(2):230-5. PubMed ID: 24372736
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Therapeutic effects of cefepime and sulbactam/cefoperazone on moderate and severe respiratory tract infection in children].
    Huang JJ; Zeng Q; Yu JL
    Di Yi Jun Yi Da Xue Xue Bao; 2005 Sep; 25(9):1199-200. PubMed ID: 16174597
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparison of cefoperazone plus sulbactam with clindamycin plus gentamicin as treatment for intra-abdominal infections.
    Greenberg RN; Cayavec P; Danko LS; Bowen K; Montazemi R; Kearney PA; Johnson SB; Strodel WE
    J Antimicrob Chemother; 1994 Sep; 34(3):391-401. PubMed ID: 7829413
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cefoperazone/sulbactam + co-trimoxazole vs ceftazidime + co-trimoxazole in the treatment of severe melioidosis: a randomized, double-blind, controlled study.
    Thamprajamchit S; Chetchotisakd P; Thinkhamrop B
    J Med Assoc Thai; 1998 Apr; 81(4):265-71. PubMed ID: 9623020
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clinical characteristics and risk factors of tigecycline-associated hypofibrinogenaemia in critically ill patients.
    Hu J; Xiao YH; Zheng Y; Lai YX; Fang XL; Fang Q
    Eur J Clin Pharmacol; 2020 Jul; 76(7):913-922. PubMed ID: 32355990
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Efficacy and safety of cefoperazone-sulbactam in empiric therapy for febrile neutropenia: A systemic review and meta-analysis.
    Lan SH; Chang SP; Lai CC; Lu LC; Tang HJ
    Medicine (Baltimore); 2020 Feb; 99(8):e19321. PubMed ID: 32080150
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.